ID   GEM-MIA PaCa-2
AC   CVCL_HA89
SY   GEM,MIA PaCa-2
DR   cancercelllines; CVCL_HA89
DR   Wikidata; Q54835559
RX   PubMed=14508125;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0428 ! MIA PaCa-2
SX   Male
AG   65Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 05-10-23; Version: 12
//
RX   PubMed=14508125; DOI=10.1097/00006676-200310000-00004;
RA   Togawa A., Ito H., Kimura F., Shimizu H., Ohtsuka M., Shimamura F.,
RA   Yoshidome H., Katoh A., Miyazaki M.;
RT   "Establishment of gemcitabine-resistant human pancreatic cancer cells
RT   and effect of brefeldin-a on the resistant cell line.";
RL   Pancreas 27:220-224(2003).
//